FDA setback for Sanofi’s Tolebrutinib in progressive MS
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Adverse events were consistent with valbenazine’s established safety profile
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Subscribe To Our Newsletter & Stay Updated